Skip to content
Investment Visual
/
Backtest
Tools
Browse
Stocks
VRTX
Financials
Revenue by product
VRTX
Vertex Pharmaceuticals Incorporated
Backtest
VRTX
Overview
Returns
Financials
Holders
Insiders
Summary
Statements
Income
Revenue
Revenue by product
Revenue by region
Gross profit
Operating income
Net income
EPS
EBITDA
Cash flow
Balance sheet
Valuation
Shares and dividends
Costs
Revenue by product
Annual
Quarterly
Revenue by product
Annual
Quarterly
2025, ended Dec 31, 2025
Trikafta/kaftrio
$10.3B
86%
Alyftrek
$838M
7%
All other
$851M
7%
Earlier:
Orkambi
to 2021
Kalydeco
to 2021
Symdeko/symkevi
to 2021
Products by fiscal year
CSV
Products by fiscal year
USD
Line, in USD
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Trikafta/kaftrio
10.3B
10.2B
8.9B
7.7B
5.7B
3.9B
420M
—
—
—
Alyftrek
838M
—
—
—
—
—
—
—
—
—
Other CF product revenues
0.82B
0.78B
0.92B
1.24B
—
—
—
—
—
—
Product revenues, net
12.0B
—
—
—
7.6B
6.2B
4.2B
3.0B
—
—
Kalydeco
—
—
—
—
0.68B
0.80B
0.99B
1.01B
0.84B
0.70B
Orkambi
—
—
—
—
0.77B
0.91B
1.33B
1.26B
1.32B
0.98B
Symdeko/symkevi
—
—
—
—
0.42B
0.63B
1.42B
0.77B
—
—
Other revenues
31M
—
—
—
1.0M
2.9M
2.1M
9.3M
323M
19M
Earlier
Other
—
—
—
—
—
—
—
—
—
610K
Total
12.0B
11.0B
9.9B
8.9B
7.6B
6.2B
4.2B
3.0B
2.5B
1.7B
More Vertex Pharmaceuticals financials
Revenue
Revenue by region
Gross profit
Operating income
Net income
EPS
Revenue at other companies
CVS
CVS Health Corporation
MCK
McKesson Corporation
BSX
Boston Scientific Corporation
ILMN
Illumina, Inc.
NTRA
Natera, Inc.
ELV
Elevance Health, Inc.
Tools
Return calculator